Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia

Neuropsychobiology

Volumn 39, Issue 2, 1999, Pages 81-85

  Takahashi, Norito ^a   Terao, Takeshi ^a   Oga, Tetsuo ^b   Okada, Masakatsu ^b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Hitachi Umegaoka Mental Hospital   (Japan)

Author keywords

5 HT(2A) receptor; Add on design; Mosapramine; Positive and negative syndrome scale for schizophrenia; Risperidone; Schizophrenia

Indexed keywords

CLOSPIPRAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 2A ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE;

EID: 0033017285     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026565     Document Type: Article

References (14)

1. Schotte A, Bonaventure P, Janssen PFM, Leysen JE: In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: Risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 1995;69:399-412.
2. Kirov GK, Murray RM, Seth RV, Feeney S: Observations on switching patients with schizophrenia to risperidone treatment. Acta Psychiatr Scand 1997;95:439-443.
3. Meltzer HY: The role of serotonin in the mechanism of action of antipsychotic drugs: Does 5-HT also have a role in the etiology of schizophrenia? Schizophr Res 1989;2:212.
4. Borison RL, Pathiraja AP, Diamond BI, Meibach RC: Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218.
5. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multi-centre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
6. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
7. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
8. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P: Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. Am J Psychiatry 1998;155:499-504.
9. Möller HJ, Gagiano CA, Addington DE, Von Knorring L, Torres-Plank JF, Gaussares C: Long-term treatment of chronic schizophrenia with risperidone: An open-label, multicenter study of 386 patients. Int Clin Psychopharmacol 1998;13:99-106.
10. Warner JP, Gledhill JA, Wakeling A: The use of risperidone in treatment-resistant schizophrenia: Two case reports. Int Clin Psychopharmacol 1996;11:65-66.
11. Henderson DC, Goff DC: Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-397.
12. Saxena S, Wang D, Bystritsky A, Baxter LR: Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306.
13. Stein DJ, Bouwer C, Hawkridge S, Emsley RA: Risperidone augmentation of scrotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-122.
14. Setoguchi M, Sakamori M, Takehara S, Fukuda T: Effect of iminodibenzyl antipsychotic drugs on cerebral dopamine and α-adrenergic receptors. Eur J Pharmacol 1985;112:313-322.